<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871802</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-AQUA-1</org_study_id>
    <nct_id>NCT04871802</nct_id>
  </id_info>
  <brief_title>Effect of the Dietary Supplement Taxifolin Aqua on the Recovery Period After COVID-19 Pneumonia</brief_title>
  <official_title>A Prospective, Randomized, Comparative Study in Two Groups to Assess the Effect of the Use of a Dietary Supplement Taxifolin Aqua on the Recovery Period After COVID Pneumonia and on the Biological Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pirogov Russian National Research Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pirogov Russian National Research Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of the study is to evaluate the effect of Taxifolin Aqua therapy on the indicators&#xD;
      of respiratory function, the state of the arterial wall, the contractile function of the&#xD;
      myocardium, as well as to assess the effect of Taxifolin Aqua therapy on markers of&#xD;
      biological age, quality of patients life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 100 patients who had covid pneumonia 3 months ago. If the inclusion /&#xD;
      exclusion criteria are met, the patient is asked to sign an informed consent to participate&#xD;
      in the study. Consenting patients are randomized to an intervention group or a control group.&#xD;
      The control group (n = 50) will receive standard therapy, patients from the intervention&#xD;
      group (n = 50) will be prescribed Taxifolin Aqua 30 mg per day in addition to standard&#xD;
      therapy. Patients will be randomized to the control and main group using random number&#xD;
      spreadsheets, assuming that the control and main groups will be homogeneous in the main&#xD;
      demographic and clinical parameters. Patient monitoring will be carried out within 2 months&#xD;
      from the date of inclusion. A follow-up visit is scheduled in 2 months. During the study, the&#xD;
      patient will be regularly monitored for tolerance and safety of therapy with Taxifolin Aqua.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamics of spirometry indices</measure>
    <time_frame>In 2 months after recruitment</time_frame>
    <description>spirometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamics of ECHO CG</measure>
    <time_frame>In 2 months after recruitment</time_frame>
    <description>ECHO CG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamics of pulse wave velocity</measure>
    <time_frame>In 2 months after recruitment</time_frame>
    <description>applanation tonometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamics of augmentation index</measure>
    <time_frame>In 2 months after recruitment</time_frame>
    <description>applanation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dynamics of biological age</measure>
    <time_frame>In 2 months after recruitment</time_frame>
    <description>Laboratory indicators</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Taxifolin Aqua group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taxifolin Aqua 30 mg per day in addition to standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Taxifolin Aqua</intervention_name>
    <description>Dietary supplement</description>
    <arm_group_label>Taxifolin Aqua group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients of both sexes who had covid pneumonia 3 months ago and signed an informed consent&#xD;
        and aged 18+.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Standard contraindications to Taxifolin Aqua use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Strazhesko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Reserach Center for Gerontology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irina Strazhesko, MD, PhD</last_name>
    <email>Istrazhesko@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Tkacheva, MD, PhD</last_name>
    <phone>+74991871254</phone>
    <email>rgnkc@rgnkc.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Russian Clinical Research Center for Gerontology</name>
      <address>
        <city>Moscow</city>
        <zip>129226</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>May 1, 2021</last_update_submitted>
  <last_update_submitted_qc>May 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Taxifolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

